Cogentus Pharmaceuticals, Inc. announced it be launching a inclusive Phase III clinical program to be a foil in favour of the efficacy and safekeeping of its new-fangled mixture analysis CGT-2168. The program, which include the COGENT-1 and COGENT-2 investigation, will enroll completed 4,000 patients at hundreds of holiday camp surrounded by the United […]
